Oxford BioMedica (LSE:OXB) COGS-to-Revenue : 0.62 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica COGS-to-Revenue?

Oxford BioMedica's Cost of Goods Sold for the six months ended in Dec. 2023 was £28.69 Mil. Its Revenue for the six months ended in Dec. 2023 was £46.48 Mil.

Oxford BioMedica's COGS to Revenue for the six months ended in Dec. 2023 was 0.62.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Oxford BioMedica's Gross Margin % for the six months ended in Dec. 2023 was 38.27%.

Oxford BioMedica COGS-to-Revenue Historical Data

The historical data trend for Oxford BioMedica's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica COGS-to-Revenue Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.56

0.47

0.42

0.51

0.56

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.35	0.44	0.56	0.49	0.62

Oxford BioMedica COGS-to-Revenue Calculation

Oxford BioMedica's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	49.812	/	89.539
	=	0.56

Oxford BioMedica's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	28.69	/	46.478
	=	0.62

Oxford BioMedica (LSE:OXB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Oxford BioMedica's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	28.69 / 46.478
	=	38.27 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Oxford BioMedica COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines